Avadel Pharmaceuticals plc Stock News

Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a m

DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that me

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that me

Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - CEO & Director Ric

DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem

DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem

Avadel's Q2 2023 earnings report shows promising growth and FDA endorsement of Lumryz for narcolepsy treatment. Lumryz has seen positive commercialization with high prescriber enrollments and reimburs

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - Chief Executive Offi

Avadel Pharmaceuticals plc finally won approval of Lumryz™ (sodium oxybate), despite cutthroat opposition from Jazz Pharmaceuticals plc. Potential sales estimate is $3bn. Avadel Pharmaceuticals is f

DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem

Avadel said it plans to launch its lead therapy to treat excessive daytime sleepiness in adults with narcolepsy, in early June. The company had no revenue in the first quarter.

Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch